ZyVersa Therapeutics to Advance Development of it's Lead Inflammasome Inhibitor with Selexis and KBI Biopharma's Integrated Development Platform
Read MoreKBI Biopharma Inc. and Selexis SA Form Joint Scientific Advisory Board Industry Experts to Provide Strategic Guidance as the Companies Advance...
CytoSen Therapeutics and KBI Biopharma Enter into Strategic Partnership to Manufacture NK Cells and NanoparticlesImplementing scalable manufacturing...
KBI in the News | KBI boosts analytical services with Belgium expansion - via BioProcess International
KBI in the News | AdAlta secures key manufacturing agreements for AD-214
KBI Biopharma BVBA Opens in Leuven, Belgium, Offering Analytical Services to the European Market
ReForm Biologics and KBI Biopharma Announce Strategic Partnership to Improve Biopharmaceutical Formulations and Development
KBI Biopharma Acquires Elion Labs to Further Expand Industry-Leading Biophysical and Analytical Characterization Capabilities
KBI Biopharma Acquires Alliance Protein Laboratories, Expands Biophysical Characterization Capabilities
JSR Life Sciences Agrees to Acquire Pioneering Cell Line Developer Selexis SA and Integrate Selexis with KBI Biopharma, Inc.
